GlassScriptPhysician profile
Raymond E Mariani
NPI 1205831724
$6,886.11
in general payments reported to CMS, 2019-2025
27 companies · $2,110 in 2025
The $2,110 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $119 · 2021: $959 · 2022: $854 · 2023: $952 · 2024: $1,474 · 2025: $2,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,535.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $876.73 | 2021-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $766.71 | 2020-2025 | Cequa |
| Apellis Pharmaceuticals, INC. | $739.84 | 2023-2025 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $601.23 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $509.28 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $386.90 | 2019-2022 | |
| Alcon Vision LLC | $379.30 | 2022-2025 | Clareon, Simbrinza, Clareon Panoptix Pro |
| Harrow Eye, LLC | $350.60 | 2024-2025 | Vevye |
| Ani Pharmaceuticals, INC. | $345.39 | 2024-2025 | Purified Cortrophin Gel |
| Biotissue Holdings INC. | $298.13 | 2022-2025 | |
| Dompe US, INC. | $291.47 | 2020-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $260.62 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $250.84 | 2022-2025 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $119.62 | 2019-2023 | Flarex |
| Allergan, INC. | $108.97 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $98.74 | 2022-2024 | |
| Glaukos Corporation | $85.54 | 2024-2025 | Photrexa Viscous and Photrexa, Photrexa |
| Mallinckrodt Enterprises LLC | $84.20 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $62.14 | 2019-2020 | |
| Sight Sciences, INC. | $40.69 | 2022-2023 | Tearcare System |
| Beaver-Visitec International, INC. | $40.61 | 2023 | |
| Rxsight INC | $40.25 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Horizon Therapeutics Plc | $39.08 | 2021 | |
| Ocular Therapeutix, INC. | $37.42 | 2023 | Dextenza |
| Rayner Intraocular Lenses Limited | $33.71 | 2024 | Omidria |
| Shire North American Group INC | $22.70 | 2019 | |
| Genentech USA, INC. | $15.40 | 2024 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Mariani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.